致：绿康生化股份有限公司 上海澄明则正律师事务所（以下简称"本所"），接受绿康生化股份有限公司 （以下简称"公司"）的委托，指派本所律师出席公司 2025 年第二次临时股东会 （以下简称"本次股东会"），并根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会 规则》（以下简称"《股东会规则》"）以及《绿康生化股份有限公司章程》（以下 简称"《公司章程》"）等规定出具《上海澄明则正律师事务所关于绿康生化股份 有限公司 2025 年第二次临时股东会之法律意见书》（以下简称"本法律意见书"）。 本所律师按照中华人民共和国（以下简称"中国"，仅为本法律意见书之目 的，不包括香港特别行政区、澳门特别行政区和台湾地区）现行法律、法规的规 定对本次股东会的召集、召开程序是否合法及是否符合《公司章程》规定、出席 会议人员资格和股东会表决程序的合法有效性发表法律意见。 上海澄明则正律师事务所 法律意见书 上海澄明则正律师事务所 关于绿康生化股份有限公司 2025 年第二次临时股东会之法律意见书 本法律意见书中不存在虚假、严重误导性陈述及重大遗漏，否则本所 ...

[Lvkang Bio 2025 Semi-Annual Performance Forecast](index=1&type=section&id=%E7%BB%BF%E5%BA%B7%E7%94%9F%E5%8C%96%E8%82%A1%E4%BB%BD%E6%9C%89%E9%99%90%E5%85%AC%E5%8F%B82025%E5%B9%B4%E5%8D%8A%E5%B9%B4%E5%BA%A6%E4%B8%9A%E7%BB%A9%E9%A2%84%E5%91%8A) [Current Period Performance Forecast](index=1&type=section&id=%E4%B8%80%E3%80%81%E6%9C%AC%E6%9C%9F%E4%B8%9A%E7%BB%A9%E9%A2%84%E8%AE%A1%E6%83%85%E5%86%B5) The company expects to record a net loss in the first half of 2025, with the loss amount projected to narrow compared to the same period last year, as net profit attributable to shareholders is estimated to be a loss of RMB 50 million to RMB 65 million, representing a year-on-year reduction in loss of 25.35% to 42.58% Performance Forecast Summary | Item | Current Period (2025 H1 Est.) | Prior Period (2024 H1) | | :--- | :--- | :--- | | **Net Profit Attributable to Shareholders** | **Loss: RMB 50 million – RMB 65 million** | Loss: RMB 87.0785 million | | | *Year-on-year reduction in loss: 25.35% – 42.58%* | | | **Net Profit Attributable to Shareholders After Non-Recurring Items** | **Loss: RMB 68 million – RMB 80 million** | Loss: RMB 104.3645 million | | | *Year-on-year reduction in loss: 23.35% – 34.84%* | | | **Basic Earnings Per Share** | **Loss: RMB 0.32/share – RMB 0.42/share** | Loss: RMB 0.56/share | [Communication with Accounting Firm](index=1&type=section&id=%E4%BA%8C%E3%80%81%E4%B8%8E%E4%BC%9A%E8%AE%A1%E5%B8%88%E4%BA%8B%E5%8A%A1%E6%89%80%E6%B2%9F%E9%80%9A%E6%83%85%E5%86%B5) This performance forecast has not been pre-audited by a certified public accountant, and its accuracy awaits final audit confirmation - This performance forecast has not been pre-audited by a certified public accountant[3](index=3&type=chunk) [Explanation of Performance Changes](index=1&type=section&id=%E4%B8%89%E3%80%81%E4%B8%9A%E7%BB%A9%E5%8F%98%E5%8A%A8%E5%8E%9F%E5%9B%A0%E8%AF%B4%E6%98%8E) The company's loss narrowed in the current period, primarily due to increased gross profit margin in the veterinary drug business and reduced inventory impairment losses - Gross profit margin for the veterinary drug business increased year-on-year due to sales growth[4](index=4&type=chunk) - The company strengthened inventory management, reduced inventory scale, and consequently decreased inventory impairment losses compared to the same period last year[4](index=4&type=chunk) [Risk Warning and Other Related Information](index=1&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA%E5%8F%8A%E5%85%B6%E4%BB%96%E7%9B%B8%E5%85%B3%E8%AF%B4%E6%98%8E) The company faces severe delisting risks due to negative net assets and an *ST designation, with potential termination of listing if 2025 financial indicators again trigger relevant regulations - The company's net assets at the end of 2024 were negative, and are expected to remain negative at the end of the first half of 2025[6](index=6&type=chunk) - The company's stock has been subject to a "delisting risk warning" (*ST) since April 30, 2025, with a daily price fluctuation limit of 5%[6](index=6&type=chunk) - If the company's audited financial indicators for the 2025 fiscal year again trigger delisting clauses, the company's stock will be terminated from listing[6](index=6&type=chunk) - This performance forecast is a preliminary calculation by the company's finance department, and the final data will be subject to the 2025 semi-annual report[6](index=6&type=chunk)

Core Viewpoint - The announcement details that certain supervisors and senior management of Green Kang Biochemical Co., Ltd. have completed their share reduction period without selling any shares, maintaining their current holdings [1][3]. Group 1: Shareholding Information - Supervisors Feng Zhenwu and Lou Lijun, along with senior manager Bao Zhongshou, have not reduced their shareholdings as of the announcement date, with their total shares remaining unchanged [1]. - The total shares held by Feng Zhenwu amount to 28,900 shares, representing 0.019% of the total share capital [2]. - Lou Lijun holds 12,500 shares, which is 0.008% of the total share capital, while Bao Zhongshou holds 27,300 shares, accounting for 0.018% of the total share capital [2]. Group 2: Compliance and Regulations - The share reduction actions are in compliance with relevant laws and regulations, including the Interim Measures for the Management of Share Reduction by Shareholders and the Self-Regulatory Guidelines for Listed Companies [3]. - The company confirms that the share reduction plan does not violate any previously disclosed plans or commitments, and there are no implications for the company's governance structure or ongoing operations [3].

证券代码：002868 证券简称：*ST 绿康 公告编号：2025-079 绿康生化股份有限公司 关于公司部分监事、高级管理人员减持期限届满暨 未减持公司股份的公告 公司监事冯真武、楼丽君，高级管理人员鲍忠寿保证向本公司提供的 信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 3、股东鲍忠寿拟自本减持计划公告之日起 15 个交易日后的 3 个月内通过集 中竞价交易方式（即2025 年4 月14 日-2025 年7 月11 日，根据相关法律法规规定 禁止减持的期间除外）减持本公司股份不超过 27,300 股（占公司总股本比例 0.018%）。 公司于今日收到冯真武、楼丽君、鲍忠寿分别出具的《关于减持期限届满暨 未减持公司股份的告知函》（以下简称"告知函"），截至本公告披露日，减持 期限届满，冯真武、楼丽君、鲍忠寿未减持公司股份，所持公司股份数量未发生 1 变化。现将有关情况公告如下： 一、股东减持股份情况 1、本次减持基本情况 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 绿康生化股份有限公司（以下简称"公司"或"绿康生化"）于 2025 年 3 月 22 日在巨潮资讯网（ ...

证券代码：002868 证券简称：*ST绿康 公告编号：2025-078 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 绿康生化股份有限公司（以下简称"公司"或"绿康生化"）于 2025 年 2 月 19 日在《 证 券 日 报 》 和 巨 潮 资 讯 网（http://www.cninfo.com.cn） 披露了《关于持股 5%以上股东解散清算暨权益变动的提示性公告》（公告编号： 2025-005），公司持股 5%以上股东杭州慈荫投资合伙企业（有限合伙）（以下简 称"慈荫投资"）经合伙人决议决定解散注销，慈荫投资将持有公司 15,541,584 股无限售流通股股票通过非交易过户至原合伙人厦门国际信托有限公司（以下 简称"厦门国际信托"）及董海名下。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 2025 年 7 月 9 日，公司收到慈荫投资的通知，其所持有的公司股份已通过 非交易过户的方式登记至各合伙人名下，相关手续已经办理完成，并已取得中 国证券登记结算有限责任公司出具的《证券过户登记确认书》，现将有关情况 公告如下： | 序 号 | 过出方 | 过入方 | 过 ...

Meeting Announcement - The company, Green Kang Biochemical Co., Ltd., has announced the second extraordinary general meeting of shareholders for 2025, scheduled for July 14, 2025, at 15:30 [1][2] - The meeting will be conducted both in-person and via online voting through the Shenzhen Stock Exchange systems [2][4] Voting Procedures - Shareholders can vote through the Shenzhen Stock Exchange trading system from 9:15 to 9:25, 9:30 to 11:30, and 13:00 to 15:00 on July 14, 2025 [1][2] - Online voting will be available from 9:15 to 15:00 on the same day [2][4] Agenda Items - The main agenda item for the meeting is to discuss the proposal to exempt the company's actual controller, directors, and senior management from voluntary shareholding restrictions [2][3] - The proposal will be voted on as a regular resolution, requiring more than half of the valid voting rights held by attending shareholders to pass [2][3] Attendance and Registration - All registered shareholders or their authorized agents can attend the meeting, and proxy representatives do not need to be shareholders [3][4] - Registration requires valid identification and authorization documents for proxy representatives [4] Additional Information - The meeting will take place at the company's office located at 6 Yuanqu Avenue, Pucheng County, Fujian Province [4] - Contact information for inquiries includes phone and fax numbers, as well as an email address [4]

证券代码：002868 证券简称：*ST 绿康 公告编号：2025-077 绿康生化股份有限公司 关于召开2025 年第二次临时股东会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 绿康生化股份有限公司（以下简称"公司"或"绿康生化"）于 2025 年 6 月 25 日召开的第五届董事会第十九次（临时）会议审议通过了《关于召开 2025 年第 二次临时股东会的议案》，决定于 2025 年 7 月 14 日 15:30 召开公司 2025 年第二 次临时股东会。具体内容详见公司于 2025 年 6 月 26 日在《证券日报》和巨潮资 讯网（http://www.cninfo.com.cn）披露的《关于召开 2025 年第二次临时股东会的 通知》（公告编号：2025-069）。 现将具体事项再次提示如下： 一、会议召开的基本情况 1、股东会届次：2025 年第二次临时股东会 2、会议召集人：公司董事会 3、会议召开的合法、合规性：本次会议的召开符合有关法律、行政法规、 部门规章、规范性文件和《公司章程》的规定。 4、现场会议召开时间：2025 年 7 ...

Core Viewpoint - The board of directors of Green康 Biochemical Co., Ltd. confirms that the parties involved in the proposed transaction do not fall under the prohibitions outlined in the regulatory guidelines regarding abnormal trading related to major asset restructuring [1][2] Group 1: Transaction Details - Green康 Biochemical Co., Ltd. plans to sell 100% equity stakes in three subsidiaries: Green康 (Yushan) Film Material Co., Ltd., Green康 (Haining) Film Material Co., Ltd., and Green康 New Energy (Shanghai) Import and Export Trade Co., Ltd. for cash [1] - The transaction is subject to the regulations set forth in the "Guidelines for the Supervision of Listed Companies No. 7" regarding major asset restructuring [1] Group 2: Compliance and Investigation Status - The company, the counterparty, and related parties, including controlling shareholders and management, have not been investigated or prosecuted for insider trading related to major asset restructuring in the last 36 months [1][2] - There are no administrative penalties or criminal responsibilities imposed by the China Securities Regulatory Commission related to insider trading for the involved parties in the specified timeframe [1][2]

绿康生化股份有限公司董事会 关于公司本次重大资产重组前 12 个月内购买、出售资产 情况的说明 绿康生化股份有限公司(以下简称"公司"或"上市公司")拟以现金方式 向江西饶信新能材料有限公司(以下简称"饶信新能")出售绿康（玉山）胶膜 材料有限公司（简称"绿康玉山"）100%股权、绿康（海宁）胶膜材料有限公 司（简称"绿康海宁"）100%股权和绿康新能（上海）进出口贸易有限公司（ 简称"绿康新能"）100%股权(以下简称"本次交易")。本次交易构成重大资 产重组。 根据《上市公司重大资产重组管理办法》规定，"上市公司在十二个月内连 续对同一或者相关资产进行购买、出售的，以其累计数分别计算相应数额。已按 照本办法的规定编制并披露重大资产重组报告书的资产交易行为，无须纳入累 计计算的范围。中国证监会对本办法第十三条第一款规定的重大资产重组的累 计期限和范围另有规定的，从其规定。交易标的资产属于同一交易方所有或者 控制，或者属于相同或者相近的业务范围，或者中国证监会认定的其他情形下， 可以认定为同一或者相关资产。" 本次交易前12个月内，公司主要资产购买或出售情况如下： 地使用权 公司于2024年3月12日召开第四 ...

Group 1 - The company plans to sell 100% equity of three subsidiaries to Jiangxi Raoxin New Energy Materials Co., Ltd. for cash [1] - The independent financial advisor conducted a review of the insider information registrant system established by the company [1][2] - The company has implemented necessary confidentiality measures and strictly controlled the personnel involved in the transaction [1][2] Group 2 - The independent financial advisor confirmed that the company adhered to relevant laws and regulations regarding the insider information registrant system [2] - The company signed confidentiality agreements with intermediary institutions to ensure the protection of sensitive information [2] - A memorandum documenting key milestones and participant details during the transaction process was maintained and signed by relevant personnel [2]